Lipid-ELISA Improves Detection of Potential PD Biomarker
By LabMedica International staff writers Posted on 31 Jul 2017 |
Image: Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the brain substantia nigra in Parkinson\'s disease (Photo courtesy of Wikimedia).
Researchers have developed a novel diagnostic approach for Parkinson’s Disease (PD), which enabled assaying of total alpha-synuclein in whole blood cells (WBC), cerebrospinal fluid (CSF), and saliva. The new ELISA assay could lead to early diagnosis and improved monitoring of PD progression and patient response to therapy.
Making an accurate diagnosis of PD is particularly difficult in early stages and mild cases. There are currently no standard diagnostic tests other than clinical information provided by the patient and findings of neurological examination. One of the best hopes for improving diagnosis is to develop a reliable test for identifying changes in the severity of the disease, which would also allow drug companies to test potential drugs at higher efficacy.
The new assay was developed by a research team at the Faculty of Medicine of the Hebrew University of Jerusalem (Jerusalem, Israel) under the supervision of Dr. Ronit Sharon. First author and PhD student Suaad Abd-Elhadi was awarded Hebrew U’s Kaye Innovation Award for 2017 in recognition of her especially important role in developing the assay.
The assay detects the protein alpha-synuclein, a potentially important PD biomarker as it is closely associated with tissues where PD can be detected and with the neurological pathways along which the disease progresses, causing its characteristic symptoms. However, ELISA capture of alpha-synuclein using antibodies raises a concern regarding efficacy for the intracellular, unfolded pool of alpha-synuclein. An alternative to antibodies is capture by membrane lipids based on utilizing the biochemical property of alpha-synuclein to specifically bind membrane lipids and to acquire a characteristic structure following binding.
They determined alpha-synuclein levels in human samples using immobilized lipids for alpha-synuclein capture. Lipids used consisted of phosphatidyl inositol (PI), phosphatidyl serine (PS), and phosphatidyl ethanolamine (PE). Addition of mono-sialoganglioside to the immobilized lipids improved the system. Following capture, the lipid-bound alpha-synuclein was detected using an anti- alpha-synuclein antibody.
The development of a simple and highly sensitive diagnostic tool that can detect PD biomarkers could lead to a minimally invasive and cost-effective way to improve the lives of Parkinson’s patients. Toward this end, the researchers have recently demonstrated a proof-of-concept to the high potential of their lipid-ELISA assay in differentiating healthy and Parkinson’s affected subjects. They are now in the process of analyzing a large cohort as part of a clinical study, including patients with moderate and severe PD. The Hebrew University has signed an agreement with Integra Holdings for further development.
The related study, Abd-Elhadi S by et al, was published November 2016 in the journal Analytical and Bioanalytical Chemistry.
Related Links:
Hebrew University of Jerusalem
Making an accurate diagnosis of PD is particularly difficult in early stages and mild cases. There are currently no standard diagnostic tests other than clinical information provided by the patient and findings of neurological examination. One of the best hopes for improving diagnosis is to develop a reliable test for identifying changes in the severity of the disease, which would also allow drug companies to test potential drugs at higher efficacy.
The new assay was developed by a research team at the Faculty of Medicine of the Hebrew University of Jerusalem (Jerusalem, Israel) under the supervision of Dr. Ronit Sharon. First author and PhD student Suaad Abd-Elhadi was awarded Hebrew U’s Kaye Innovation Award for 2017 in recognition of her especially important role in developing the assay.
The assay detects the protein alpha-synuclein, a potentially important PD biomarker as it is closely associated with tissues where PD can be detected and with the neurological pathways along which the disease progresses, causing its characteristic symptoms. However, ELISA capture of alpha-synuclein using antibodies raises a concern regarding efficacy for the intracellular, unfolded pool of alpha-synuclein. An alternative to antibodies is capture by membrane lipids based on utilizing the biochemical property of alpha-synuclein to specifically bind membrane lipids and to acquire a characteristic structure following binding.
They determined alpha-synuclein levels in human samples using immobilized lipids for alpha-synuclein capture. Lipids used consisted of phosphatidyl inositol (PI), phosphatidyl serine (PS), and phosphatidyl ethanolamine (PE). Addition of mono-sialoganglioside to the immobilized lipids improved the system. Following capture, the lipid-bound alpha-synuclein was detected using an anti- alpha-synuclein antibody.
The development of a simple and highly sensitive diagnostic tool that can detect PD biomarkers could lead to a minimally invasive and cost-effective way to improve the lives of Parkinson’s patients. Toward this end, the researchers have recently demonstrated a proof-of-concept to the high potential of their lipid-ELISA assay in differentiating healthy and Parkinson’s affected subjects. They are now in the process of analyzing a large cohort as part of a clinical study, including patients with moderate and severe PD. The Hebrew University has signed an agreement with Integra Holdings for further development.
The related study, Abd-Elhadi S by et al, was published November 2016 in the journal Analytical and Bioanalytical Chemistry.
Related Links:
Hebrew University of Jerusalem
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms